KZA 0.00% 8.0¢ kazia therapeutics limited

The interim DIPG combo data is imminent if the schedule of...

  1. 114 Posts.
    lightbulb Created with Sketch. 125

    The interim DIPG combo data is imminent if the schedule of milestones is somewhat correct and there are a few conferences in the coming 4 months, most notably SNO in June where the DIPG data is well placed.
    https://www.soc-neuro-onc.org/WEB/WEB/Events.aspx

    If the data is relatively in line with the experience from case reports then I translate previous JG's comments on the willingness of regulatory bodies to look at the evidence in such underserved, high-need areas as "We will align our regulatory strategy with Chimerix and prepare the documents for a (conditional) regulatory approval".
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.